Canaccord analyst Whitney Ijem lowered the firm’s price target on Alnylam to $288 from $291 and keeps a Buy rating on the shares. The firm updated its model following the CRL from the FDA on Onpattro TTR-CM. As such, it removed its revenue from its model but they believe the shares are already pricing in minimal CM credit and thus they see relatively limited downside from current levels on a DCF basis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALNY:
- Alnylam price target lowered to $218 from $237 at Bernstein
- Alnylam price target lowered to $210 from $252 at Evercore ISI
- Alnylam price target lowered to $260 from $265 at TD Cowen
- Alnylam price target lowered to $234 from $250 at BMO Capital
- BridgeBio has positive readthrough from Alnylam’s CRL, says BofA